TY - JOUR T1 - Cinacalcet in the management of normocalcaemic secondary hyperparathyroidism after kidney transplantation: one-year follow-up multicentre study JO - Nefrología (English Edition) T2 - AU - Torregrosa,Josep V. AU - Morales,Enrique AU - Díaz,Juan M. AU - Crespo,Josep AU - Bravo,Juan AU - Gómez,Gonzalo AU - Gentil,Miguel A. AU - Rodríguez-Benot,Alberto AU - Rodríguez-García,Minerva AU - López-Jiménez,Verónica AU - Gutiérrez-Dalmau,Álex AU - Jimeno,Luisa AU - Pérez-Sáez,M. José AU - Romero,Rafael AU - Gómez-Alamillo,Carlos SN - 20132514 M3 - 10.3265/Nefrologia.pre2013.Aug.12183 DO - 10.3265/Nefrologia.pre2013.Aug.12183 UR - https://www.revistanefrologia.com/en-cinacalcet-in-management-normocalcaemic-secondary-articulo-X2013251414053646 AB - Background: The effect of cinacalcet in patients with persistent secondary hyperparathyroidism (SHPT) after kidney transplantation (RT) has mainly been reported in patients with secondary hypercalcaemia. Objectives: Our objective was to assess the long-term effect of cinacalcet on patients with a RT and normocalcaemic SHPT. Methods: A one-year multicentre, observational, retrospective study that included kidney recipients with SHPT (intact parathyroid hormone [iPTH] >120pg/ml) and calcium levels within the normal range (8.4-10.2mg/dl). Patients began treatment with cinacalcet in clinical practice. Results: 32 patients with a mean age (standard deviation [SD]) of 54 (11) years, 56% male, were included in the study. Treatment with cinacalcet began a median of 16 months after RT (median dose of 30mg/day). Levels of iPTH decreased from a median (P25, P75) of 364 (220, 531) pg/ml at the start of the study to 187 (98, 320) after 6 months (48.6% reduction, P=.001) and to 145 (91, 195) after 12 months (60.2% reduction, P=.001), without there being changes in calcium and phosphorus levels (P=.214 and P=.216, respectively). No changes were observed in kidney function or anti-calcineuric drug levels. 3.1% of patients discontinued cinacalcet due to intolerance and 6.2% due to a lack of efficacy. Conclusions: In patients with normocalcaemic SHPT after RT, cinacalcet improves the control of serum PTH values without causing changes to calcaemia, phosphataemia or kidney function. Cinacalcet showed good tolerability.  ER -